Niacin, an old drug with a new twist

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2586-2594

  Song, Wen Liang ^a,b   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

Author keywords

Cardiovascular; Cholesterol; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; CLOFIBRATE; COLESTIPOL; DEXTROTHYROXINE; ESTROGEN; EZETIMIBE; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; PROTEIN GPR109A; SIMVASTATIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BLEEDING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GOUT; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INDIGESTION; INFECTION; INSULIN SENSITIVITY; LIVER TOXICITY; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

CARDIOVASCULAR; CHOLESTEROL; PROSTAGLANDIN;

ANIMALS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884153189     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R040592     Document Type: Review

References (124)

1. Carlson, L. A. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258: 94-114.
2. Niehoff, I. D., L. Huther, and P. Lebzien. 2009. Niacin for dairy cattle: a review. Br. J. Nutr. 101: 5-19.
3. Altschul, R., A. Hoffer, and J. D. Stephen. 1955. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. 54: 558-559.
4. Meyers, C. D., V. S. Kamanna, and M. L. Kashyap. 2004. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 15: 659-665.
5. Tunaru, S., J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, and S. Offermanns. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9: 352-355.
6. Wise, A., S. M. Foord, N. J. Fraser, A. A. Barnes, N. Elshourbagy, M. Eilert, D. M. Ignar, P. R. Murdock, K. Steplewski, A. Green, et al. 2003. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278: 9869-9874.
7. Soga, T., M. Kamohara, J. Takasaki, S. Matsumoto, T. Saito, T. Ohishi, H. Hiyama, A. Matsuo, H. Matsushime, and K. Furuichi. 2003. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303: 364-369.
8. Tunaru, S., J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, and S. Offermanns. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9: 352-355.
9. Benyó, Z., A. Gille, J. Kero, M. Csiky, M. C. Suchá noková, R. M. Nüsing, A. Moers, K. Pfeffer, and S. Offermanns. 2005. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115: 3634-3640.
10. Hanson, J., A. Gille, S. Zwykiel, M. Lukasova, B. E. Clausen, K. Ahmed, S. Tunaru, A. Wirth, and S. Offermanns. 2010. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 120: 2910-2919.
11. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub; AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
12. HPS2-THRIVE Collaborative Group. 2013. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34: 1279-1291.
13. Parsons, W. B., Jr ., and J. H. Flinn. 1959. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch. Intern. Med. 103: 783-790.
14. Birjmohun, R. S., B. A. Hutten, J. J. Kastelein, and E. S. Stroes. 2005. Efficacy and safety of high-density lipoprotein cholesterolincreasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45: 185-197.
15. Carlson, L. A., A. Hamsten, and A. Asplund. 1989. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J. Intern. Med. 226: 271-276.
16. Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24: 2219-2226.
17. Carlson, L. A., and L. Oro. 1962. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med. Scand. 172: 641-645.
18. Carlson, L. A. 1963. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med. Scand. 173: 719-722.
19. Butcher, R. W., C. E. Baird, and E. W. Sutherland. 1968. Effects of lipolytic and antilipolytic substances on adenosine 3 ', 5 ' - monophosphate levels in isolated fat cells. J. Biol. Chem. 243: 1705-1712.
20. Carlson, L. A., L. Oro, and J. Ostman. 1968. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med. Scand. 183: 457-465.
21. Carlson, L. A., and L. Oroe. 1965. Persistence of the inhibitory effect of nicotinic acid on catecholamine-stimulated lipid mobilization during prolonged treatment with nicotinic acid. J. Atheroscler. Res. 5: 436-439.
22. Stern, R. H., J. D. Spence, D. J. Freeman, and A. Parbtani. 1991. Tolerance to nicotinic acid flushing. Clin. Pharmacol. Ther. 50: 66-70.
23. Lewis, G. F. 1997. Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipidol. 8: 146-153.
24. Lauring, B., A. K. Taggart, J. R. Tata, R. Dunbar, L. Caro, K. Cheng, J. Chin, S.L. Colletti, J. Cote, S. Khalilieh, et al. 2012. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 4: 148ra115.
25. Jin, F. Y., V. S. Kamanna, and M. L. Kashyap. 1997. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 17: 2020-2028.
26. Ganji, S. H., S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, and M. L. Kashyap. 2004. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res. 45: 1835-1845.
27. Szapary, P. O., and D. J. Rader. 2001. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Curr. Opin. Pharmacol. 1: 113-120.
28. Le Goff, W., M. Guerin, and M. J. Chapman. 2004. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101: 17-38.
29. Yvan-Charvet, L., J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher, C.P. Sparrow, A. K. Taggart, and A. R. Tall. 2010. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30: 1430-1438.
30. Hernandez, C., M. Molusky, Y. Li, S. Li, and J. D. Lin. 2010. Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid. Cell Metab. 12: 411-419.
31. Lamon-Fava, S., M. R. Diffenderfer, P. H. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, M. R. Matthan, et al. 2008. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28: 1672-1678.
32. Offermanns, S. 2012. It ain't over 'til the fat lady sings. Sci. Transl. Med. 4: 148fs130.
33. Blum, C. B., R. I. Levy, S. Eisenberg, M. Hall 3rd, R. H. Goebel, and M. Berman. 1977. High density lipoprotein metabolism in man. J. Clin. Invest. 60: 795-807.
34. Shepherd, J., C. J. Packard, J. R. Patsch, A. M. Gotto, Jr ., and O. D. Taunton. 1979. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest. 63: 858-867.
35. Gille, A., E. T. Bodor, K. Ahmed, and S. Offermanns. 2008. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48: 79-106.
36. Nordestgaard, B. G., M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, et al. 2010. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31: 2844-2853.
37. Kamstrup, P. R., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 2011. Lipoprotein(a) and risk of myocardial infarction-genetic epidemiologic evidence of causality. Scand. J. Clin. Lab. Invest. 71: 87-93.
38. Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 102: 1082-1085.
39. Smolders, B., R. Lemmens, and V. Thijs. 2007. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke. 38: 1959-1966.
40. Schreiner, P. J., J. D. Morrisett, A. R. Sharrett, W. Patsch, H. A. Tyroler, K. Wu, and G. Heiss. 1993. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler. Thromb. 13: 826-833.
41. Berglund, L. 1995. Diet and drug therapy for lipoprotein (a). Curr. Opin. Lipidol. 6: 48-56.
42. Tornvall, P., and G. Walldius. 1991. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia-effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J. Intern. Med. 230: 415-421.
43. Fuccella, L. M., G. Goldaniga, P. Lovisolo, E. Maggi, L. Musatti, V. Mandelli, and C. R. Sirtori. 1980. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin. Pharmacol. Ther. 28: 790-795.
44. Soudijn, W., I. van Wijngaarden, and A. P. Ijzerman. 2007. Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev. 27: 417-433.
45. Wang, M., and C. Fotsch. 2006. Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes. Chem. Biol. 13: 1019-1027.
46. van Herk, T., J. Brussee, A. M. van den Nieuwendijk, P. A. van der Klein, A. P. IJzerman, C. Stannek, A. Burmeiter, and A. Lorenzen. 2003. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J. Med. Chem. 46: 3945-3951.
47. Semple, G., P. J. Skinner, M. C. Cherrier, P. J. Webb, C. R. Sage, S. Y. Tamura, R. Chen, J. G. Richman, and D. T. Connolly. 2006. 1-Alkyl-benzotriazole- 5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J. Med. Chem. 49: 1227-1230.
48. Walters, R. W., A. K. Shukla, J. J. Kovacs, J. D. Violin, S. M. DeWire, C. M. Lam, J. R. Chen, M. J. Muehlbauer, E. J. Whalen, and R. J. Lefkowitz. 2009. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Invest. 119: 1312-1321.
49. Lai, E., M. G. Waters, J. R. Tata, W. Radziszewski, I. Perovozskaya, W. Zhen, L. Wenning, D. T. Connolly, G. Semple, A. O. Johnson- Levonas, et al. 2008. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J. Clin. Lipidol. 2: 375-383.
50. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
51. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Hólm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 380: 572-580.
52. Rader, D. J., and A. R. Tall. 2012. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18: 1344-1346.
53. Wu, B. J., L. Yan, F. Charlton, P. Witting, P. J. Barter, and K. A. Rye. 2010. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30: 968-975.
54. Lukasova, M., C. Malaval, A. Gille, J. Kero, and S. Offermanns. 2011. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121: 1163-1173.
55. Holzhäuser, E., C. Albrecht, Q. Zhou, A. Buttler, M. R. Preusch, E. Blessing, H. A. Katus, and F. Bea. 2011. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. J. Cardiovasc. Pharmacol. 57: 447-454.
56. Yu, B. L., and S. P. Zhao. 2007. Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipidaltering effects. Med. Hypotheses. 69: 90-94.
57. Tavintharan, S., S. C. Lim, and C. F. Sum. 2009. Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin. Pharmacol. Toxicol. 104: 206-210.
58. Knowles, H. J., R. H. te Poele, P. Workman, and A. L. Harris. 2006. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 71: 646-656.
59. [Erratum. 2006. Biochem. Pharmacol. 71: 1662.]
60. Rubic, T., M. Trottmann, and R. L. Lorenz. 2004. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67: 411-419.
61. Plaisance, E. P., M. Lukasova, S. Offermanns, Y. Zhang, G. Cao, and R. L. Judd. 2009. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am. J. Physiol. Endocrinol. Metab. 296: E549 - E558.
62. Westphal, S., and C. Luley. 2008. Preferential increase in highmolecular weight adiponectin after niacin. Atherosclerosis. 198: 179-183.
63. Song, W. L., J. Stubbe, E. Ricciotti, N. Alamuddin, S. Ibrahim, I. Crichto, M. Prempeh, J. A. Lawson, R. L. Wilensky, L. M. Rasmussen, et al. 2012. Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans. J. Clin. Invest. 122: 1459-1468.
64. Saareks, V., I. Mucha, E. Sievi, and A. Riutta. 1999. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol. Toxicol. 84: 274-280.
65. Degoma, E. M., and D. J. Rader. 2011. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 8: 266-277.
66. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
67. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108: 661-663.
68. Pászty, C., N. Maeda, J. Verstuyft, and E. M. Rubin. 1994. Apolipoprotein AI transgene corrects apolipoprotein E deficiency- induced atherosclerosis in mice. J. Clin. Invest. 94: 899-903.
69. Weng, W., and J. L. Breslow. 1996. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. USA. 93: 14788-14794.
70. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1241.
71. Badimon, J. J., L. Badimon, A. Galvez, R. Dische, and V. Fuster. 1989. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. 60: 455-461.
72. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
73. Dunbar, R. L., and J. M. Gelfand. 2010. Seeing red: flushing out instigators of niacin-associated skin toxicity. J. Clin. Invest. 120: 2651-2655.
74. Morrow, J. D., W. G. Parsons 3rd, and L. J. Roberts 2nd. 1989. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 38: 263-274.
75. Morrow, J. D., J. A. Awad, J. A. Oates, and L. J. Roberts 2nd. 1992. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98: 812-815.
76. Lauring, B., V. Dishy, W. L. Luo, O. Laterza, J. Patterson, J. Cote, A. Chao, P. Larson, M. Gutierrez, J. A. Wagner, et al. 2009. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J. Clin. Pharmacol. 49: 1426-1435.
77. Truelove, L. H., and J. J. Duthie. 1959. Effect of aspirin on cutaneous response to the local application of an ester of nicotinic acid. Ann. Rheum. Dis. 18: 137-141.
78. Cefali, E. A., P. D. Simmons, E. J. Stanek, M. E. McGovern, and C. J. Kissling. 2007. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int. J. Clin. Pharmacol. Ther. 45: 78-88.
79. Jungnickel, P. W., P. A. Maloley, E. L. Vander Tuin, T. E. Peddicord, and J. R. Campbell. 1997. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J. Gen. Intern. Med. 12: 591-596.
80. Parson, H. K., H. Harati, D. Cooper, and A. I. Vinik. 2013. Role of prostaglandin D2 and the autonomic nervous system in niacininduced flushing. J. Diabetes. 5: 59-67.
81. Cheng, K., T. J. Wu, K. K. Wu, C. Sturino, K. Metters, K. Gottesdiener, S. D. Wright, Z. Wang, G. O'Neill, E. Lai, et al. 2006. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA. 103: 6682-6687.
82. Lai, E., I. De Lepeleire, T. M. Crumley, F. Liu, L. A. Wenning, N. Michiels, E. Vets, G. O'Neill, J. A. Wagner, and K. Gottesdiener. 2007. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81: 849-857.
83. Maccubbin, D., M. J. Koren, M. Davidson, D. Gavish, R. C. Pasternak, G. Macdonell, M. Mallick, C. M. Sisk, J. F. Paolini, and Y. Mitchel. 2009. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am. J. Cardiol. 104: 74-81.
84. Paolini, J. F., Y. B. Mitchel, R. Reyes, U. Kher, E. Lai, D. J. Watson, J. M. Norquist, A. G. Meehan, H. E. Bays, M. Davidson, et al. 2008. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol. 101: 625-630.
85. Kush, D., D. Y. Hu, P. Ye, H. S. Kim, E. Chen, W. Sirah, C. McCrary Sisk, J. F. Paolini, and D. Maccubbin. 2009. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. 114: 192-198.
86. Maccubbin, D., H. E. Bays, A. G. Olsson, V. Elinoff, A. Ellis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, et al. 2008. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int. J. Clin. Pract. 62: 1959-1970.
87. Kush, D., H. S. Kim, Y. Hu da, J. Liu, W. Sirah, A. Sapre, C. McCrary Sisk, J. F. Paolini, and D. Maccubbin. 2009. Lipid-modifying effi- cacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. J. Clin. Lipidol. 3: 179-186.
88. Bays, H., A. Shah, Q. Dong, C. McCrary Sisk, and D. Maccubbin. 2011. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int. J. Clin. Pract. 65: 436-445.
89. Bays, H. E., A. Shah, J. Lin, C. McCrary Sisk, J. F. Paolini, and D. Maccubbin. 2010. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J. Clin. Lipidol. 4: 515-521.
90. Ballantyne, C., G. Gleim, N. Liu, C. M. Sisk, A. O. Johnson-Levonas, and Y. Mitchel. 2012. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J. Clin. Lipidol. 6: 235-243.
91. Chen, F., D. Maccubbin, L. Yan, W. Sirah, E. Chen, C. M. Sisk, M. Davidson, P. Blomqvist, and J. M. McKenney. 2013. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int. J. Cardiol. 167: 225-231.
92. Miettinen, T. A., M. R. Taskinen, R. Pelkonen, and E. A. Nikkila. 1969. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med. Scand. 186: 247-253.
93. Poynten, A. M., S. K. Gan, A. D. Kriketos, A. O'Sullivan, J. J. Kelly, B. A. Ellis, D. J. Chisholm, and L. V. Campbell. 2003. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism. 52: 699-704.
94. Canner, P. L., C. D. Furberg, M. L. Terrin, and M. E. McGovern. 2005. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 95: 254-257.
95. Ridker, P. M., E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359: 2195-2207.
96. Sattar, N., D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley, A. J. de Craen, S. R. Seshasai, J. J. McMurray, D. J. Freeman, J. W. Jukema, et al. 2010. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375: 735-742.
97. Shah, R. V., and A. B. Goldfine. 2012. Statins and risk of new-onset diabetes mellitus. Circulation. 126: e282 - e284.
98. Andersson, S., L. A. Carlson, L. Oro, and E. A. Richards. 1971. Effect of nicotinic acid on gastric secretion of acid in human subjects and in dogs. Scand. J. Gastroenterol. 6: 693-698.
99. Lawrence, S. P. 1993. Transient focal hepatic defects related to sustained-release niacin. J. Clin. Gastroenterol. 16: 234-236.
100. Dalton, T. A., and R. S. Berry. 1992. Hepatotoxicity associated with sustained-release niacin. Am. J. Med. 93: 102-104.
101. Etchason, J. A., T. D. Miller, R. W. Squires, T. G. Allison, G. T. Gau, J. K. Marttila, and B. A. Kotke. 1991. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin. Proc. 66: 23-28.
102. McKenney, J. 2004. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164: 697-705.
103. Gershon, S. L., and I. H. Fox. 1974. Pharmacologic effects of nicotinic acid on human purine metabolism. J. Lab. Clin. Med. 84: 179-186.
104. Fitzpatrick, D. A., O. FitzGerald, and K. F. McGeeney. 1969. Nicotinic acid inhibition of uricase. Ir. J. Med. Sci. 8: 531-534.
105. Gaut, Z. N., R. Pocelinko, H. M. Solomon, and G. B. Thomas. 1971. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism. 20: 1031-1035.
106. 1975. Clofibrate and niacin in coronary heart disease. JAMA. 231: 360-381.
107. Canner, P. L., K. G. Berge, N. K. Wenger, J. Stamler, L. Friedman, R. J. Prineas, and W. Friedewald. 1986. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8: 1245-1255.
108. Carlson, L. A., and G. Rosenhamer. 1988. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223: 405-418.
109. Brown, G., J. J. Albers, L. D. Fisher, S. M. Schaefer, J. T. Lin, C. Kaplan, X. Q. Zhao, B. D. Bisson, V. F. Fitzpatrick, and H. T. Dodge. 1990. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323: 1289-1298.
110. Brown, B. G., X. Q. Zhao, A. Chait, L. D. Fisher, M. C. Cheung, J. S. Morse, A. A. Dowdy, E. K. Marino, E. L. Bolson, P. Alaupovic, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345: 1583-1592.
111. Taylor, A. J., L. E. Sullenberger, H. J. Lee, J. K. Lee, and K. A. Grace. 2004. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double- blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 110: 3512-3517.
112. Taylor, A. J., H. J. Lee, and L. E. Sullenberger. 2006. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22: 2243-2250.
113. Taylor, A. J., T. C. Villines, E. J. Stanek, P. J. Devine, L. Griffen, M. Miller, N. J. Weissman, and M. Turco. 2009. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361: 2113-2122.
114. Lee, J. M., M. D. Robson, L. M. Yu, C. C. Shirodaria, C. Cunnington, I. Dylintireas, J. E. Digby, T. Bannister, A. Handa, F. Wiesmann, et al. 2009. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebocontrolled, magnetic resonance imaging study. J. Am. Coll. Cardiol. 54: 1787-1794.
115. Michos, E. D., C. T. Sibley, J. T. Baer, M. J. Blaha, and R. S. Blumenthal. 2012. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J. Am. Coll. Cardiol. 59: 2058-2064.
116. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
117. Rosenson, R. S., and A. M. Gotto, Jr. 2013. When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. Curr. Atheroscler. Rep. 15: 332.
118. Thompson, P. D., P. Clarkson, and R. H. Karas. 2003. Statinassociated myopathy. JAMA. 289: 1681-1690.
119. Rajakariar, R., M. Hilliard, T. Lawrence, S. Trivedi, P. Colville- Nash, G. Bellingan, D. Fitzgerald, M. M. Yagoob, and D. W. Gilroy. 2007. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc. Natl. Acad. Sci. USA. 104: 20979-20984.
120. Murata, T., K. Aritake, Y. Tsubosaka, T. Maruyama, T. Nakagawa, M. Hori, H. Hirai, M. Nakamura, S. Narumiya, Y. Urade, et al. 2013. Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement. Proc. Natl. Acad. Sci. USA. 110: 5205-5210.
121. Brown, S. L., B. E. Sobel, and S. Fujii. 1995. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation. 92: 767-772.
122. Chesney, C. M., M. B. Elam, J. A. Herd, K. B. Davis, R. Garg, D. Hunninghake, J. W. Kennedy, and W. B. Applegate. 2000. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am. Heart J. 140: 631-636.
123. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, et al. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.
124. Strack, A. M., E. Carballo-Jane, S. P. Wang, J. Xue, X. Ping, L. A. McNamara, A. Thankappan, O. Price, M. Wolff, T. J. Wu, et al. 2013. Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis. J. Lipid Res. 54: 177-188.